Imunon Price To Sales Ratio from 2010 to 2024

IMNN Stock  USD 0.84  0.06  6.64%   
Imunon Price To Sales Ratio yearly trend continues to be very stable with very little volatility. Price To Sales Ratio is likely to drop to 21.07. Price To Sales Ratio is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing Imunon's market cap by its total sales or revenue over a 12-month period. View All Fundamentals
 
Price To Sales Ratio  
First Reported
2010-12-31
Previous Quarter
22.18
Current Value
21.07
Quarterly Volatility
73.28365007
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Imunon financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Imunon's main balance sheet or income statement drivers, such as Depreciation And Amortization of 408.9 K, Interest Expense of 206.9 M or Selling General Administrative of 6.2 M, as well as many indicators such as Price To Sales Ratio of 21.07, Dividend Yield of 0.0 or PTB Ratio of 0.48. Imunon financial statements analysis is a perfect complement when working with Imunon Valuation or Volatility modules.
  
Check out the analysis of Imunon Correlation against competitors.

Latest Imunon's Price To Sales Ratio Growth Pattern

Below is the plot of the Price To Sales Ratio of Imunon Inc over the last few years. Price to Sales Ratio is figured by comparing Imunon Inc stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Imunon sales, a figure that is much harder to manipulate than other Imunon Inc multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Imunon's Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Imunon's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 17.94 X10 Years Trend
Slightly volatile
   Price To Sales Ratio   
       Timeline  

Imunon Price To Sales Ratio Regression Statistics

Arithmetic Mean72.77
Geometric Mean51.05
Coefficient Of Variation100.71
Mean Deviation46.43
Median49.58
Standard Deviation73.28
Sample Variance5,370
Range293
R-Value(0.56)
Mean Square Error3,965
R-Squared0.31
Significance0.03
Slope(9.19)
Total Sum of Squares75,187

Imunon Price To Sales Ratio History

2024 21.07
2023 22.18
2022 19.29
2021 93.48
2020 45.38
2019 74.67
2018 49.58

About Imunon Financial Statements

Imunon investors utilize fundamental indicators, such as Price To Sales Ratio, to predict how Imunon Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Price To Sales Ratio 22.18  21.07 

Pair Trading with Imunon

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Imunon position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Imunon will appreciate offsetting losses from the drop in the long position's value.

Moving together with Imunon Stock

  0.79VALN Valneva SE ADRPairCorr
  0.69ERNA Eterna TherapeuticsPairCorr

Moving against Imunon Stock

  0.84BMY Bristol Myers SquibbPairCorr
  0.75GILD Gilead SciencesPairCorr
  0.59ESPR Esperion TherapeuticsPairCorr
  0.43DYAI Dyadic InternationalPairCorr
The ability to find closely correlated positions to Imunon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Imunon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Imunon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Imunon Inc to buy it.
The correlation of Imunon is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Imunon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Imunon Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Imunon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Imunon Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Imunon's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Imunon Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Imunon Inc Stock:
Check out the analysis of Imunon Correlation against competitors.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Imunon. If investors know Imunon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Imunon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.91)
Revenue Per Share
0.014
Return On Assets
(0.67)
Return On Equity
(1.48)
The market value of Imunon Inc is measured differently than its book value, which is the value of Imunon that is recorded on the company's balance sheet. Investors also form their own opinion of Imunon's value that differs from its market value or its book value, called intrinsic value, which is Imunon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Imunon's market value can be influenced by many factors that don't directly affect Imunon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Imunon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Imunon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Imunon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.